<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Hertz | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/inchkorean7/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/inchkorean7/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Hertz.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">889f215150a9f8009ba99dd047e91677</guid>
				<title>Hertz posted an update: In patients with N3 head and neck squamous cell carcinoma [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/38929/</link>
				<pubDate>Wed, 05 Feb 2025 09:19:55 -0800</pubDate>

									<content:encoded><![CDATA[<p>In patients with N3 head and neck squamous cell carcinoma (HNSCC), N3 disease is associated with high regional relapse and metastatic risks. Patients with resectable N3 disease have better prognosis although their metastatic risk may be similar as in patients with unresectable disease. Neoadjuvant chemotherapy has been associated with lower&hellip;<span class="activity-read-more" id="activity-read-more-38929"><a href="http://www.nationalboardinstitute.com/activity/p/38929/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">71e840da9f0f699360d17ebff0844dd8</guid>
				<title>Hertz posted an update: Venous thromboembolism (VTE) is a common cause of morbidity [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/36225/</link>
				<pubDate>Sun, 02 Feb 2025 09:05:40 -0800</pubDate>

									<content:encoded><![CDATA[<p>Venous thromboembolism (VTE) is a common cause of morbidity and mortality. Although most patients can be managed safely with anticoagulation, inferior vena cava filters (IVCFs) represent an important alternative to anticoagulation in a small subset of patients. IVCF use has expanded exponentially with the advent of retrievable filters. Indications&hellip;<span class="activity-read-more" id="activity-read-more-36225"><a href="http://www.nationalboardinstitute.com/activity/p/36225/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">b3bd548ec84a3a262cd48947dea0a1e7</guid>
				<title>Hertz posted an update: Serum AMH level has been shown to decrease in women treated [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/29284/</link>
				<pubDate>Tue, 28 Jan 2025 13:01:26 -0800</pubDate>

									<content:encoded><![CDATA[<p>Serum AMH level has been shown to decrease in women treated for breast cancer in several studies. However, whether basal AMH status affects AMH dynamics during chemotherapy remains to be clarified. The objective of this study was to compare serum AMH dynamics in young women with either low, normal or high basal serum AMH level at diagnosis, during&hellip;<span class="activity-read-more" id="activity-read-more-29284"><a href="http://www.nationalboardinstitute.com/activity/p/29284/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">cac0f8516c52dabbde7cff961828d8ba</guid>
				<title>Hertz became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/29240/</link>
				<pubDate>Tue, 28 Jan 2025 12:59:18 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>